Swiss Cardio Technologies
Swiss Cardio Technologies AG is a Swiss specialty pharmaceutical company founded in 2008 as a University of Berne spin-off; it holds the exclusive global license for Cardioplexol®, a standardized ultra-low-volume cardioplegic solution for cardiovascular surgery, serving hospitals and cardiac surgery centers via regional distributors in Switzerland and the EU.
- Company typePrivate
- Founded2008
- HeadquartersStansstad, Switzerland
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Swiss Cardio Technologies does
Swiss Cardio Technologies AG is a privately held Swiss specialty pharmaceutical company founded in 2008 as a spin-off from the University of Berne by a group of cardiovascular surgery specialists. The company is the exclusive global license holder of Cardioplexol®, a novel standardized ultra-low-volume cardioplegic solution used to induce cardiac arrest and provide myocardial protection during cardiovascular surgery. Its core customers are hospitals and cardiovascular surgery centers requiring standardized cardioplegic formulations for surgical procedures.
The company's revenue model is built on pharmaceutical product sales of Cardioplexol® marketed through regional distribution partnerships: Medius AG handles Switzerland and TAW Pharma (Ireland) Limited handles Europe. Swiss Cardio Technologies has secured marketing approvals in 10 EU countries plus Switzerland, creating a multi-jurisdiction regulatory platform that underpins its commercial rollout. The company holds a registered trademark for Cardioplexol® and operates with a small core team of cardiovascular surgeons, perfusionists, industrial pharmacists, chemists, and a governing board including academic cardiovascular-surgery strategic advisors.
In 2024, Swiss Cardio Technologies was acquired by Denmark-based Abacus Medicine Group, a strategic pharmaceutical acquirer, with the deal conferring worldwide rights to the cardioplegia business. The acquisition was publicly confirmed in August 2025 via a press release on the company's website. The transaction signals a strategic intent to accelerate global commercialization of Cardioplexol® and embed it within Abacus's broader European hospital-channel infrastructure. Pricing is not publicly disclosed, and no revenue, funding-round, or headcount figures are available in the public sources.
Swiss Cardio Technologies firmographics
Firmographics- Name
- Swiss Cardio Technologies
- Legal name
- Swiss Cardio Technologies AG
- Website
- https://swisscardiotech.com
- Company type
- Private
- Founded year
- 2008
- Operating status
- Acquired
- Headcount range
- 1–10 employees
- Short description
- Swiss Cardio Technologies AG is a Swiss specialty pharmaceutical company founded in 2008 as a University of Berne spin-off; it holds the exclusive global license for Cardioplexol®, a standardized ultra-low-volume cardioplegic solution for cardiovascular surgery, serving hospitals and cardiac surgery centers via regional distributors in Switzerland and the EU.
- Ownership category
- akta.pro rank
Swiss Cardio Technologies industry classification
Industry- Product category
- Cardiovascular Pharmaceuticals
- NAICS
- Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (42345)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG)
- akta.pro secondary industry
- Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)
Keywords
Where Swiss Cardio Technologies is headquartered
LocationHeadquarters
- HQ city
- Stansstad
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
Swiss Cardio Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Pharmaceutical product sales: Revenue generated through the sale of Cardioplexol, a cardioplegic solution for cardiovascular surgery. The product is marketed by Medius AG in Switzerland and TAW Pharma in Europe, with worldwide rights acquired by Abacus Medicine Group in 2024.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels1 record
Swiss Cardio Technologies product offering
Product offeringCore offering
Swiss Cardio Technologies AG develops and commercializes Cardioplexol®, a novel standardized ultra-low-volume cardioplegic solution used in cardiovascular surgery to provide myocardial protection during operative procedures. The company holds exclusive global license rights to Cardioplexol® and has obtained marketing approvals in 10 EU countries and Switzerland, distributing the product through pharmaceutical partners Medius AG (Switzerland) and TAW Pharma (Europe).
Product overview
Swiss Cardio Technologies is a single-product medical technology company focused on its flagship cardioplegic solution Cardioplexol®, a standardized ultra-low-volume solution for cardiovascular surgery. The company operates as a spin-off from the University of Berne (founded 2008) and was acquired by Denmark-based Abacus Medicine Group in 2024/2025. Cardioplexol® is marketed through distribution partners Medius AG (Switzerland) and TAW Pharma (Ireland) in Europe.
Differentiator
Problem solved
Functional benefit
Brands
- Cardioplexol®: A novel standardized ultra-low-volume cardioplegic solution developed by Swiss Cardio Technologies AG for use in cardiovascular surgery.
Products and services
- Cardioplexol®
Companies that use Swiss Cardio Technologies
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Swiss Cardio Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Swiss Cardio Technologies partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered flagship and core.
- Abacus Medicine GroupflagshipAbacus Medicine Group, a Denmark-based pharmaceutical company, acquired Swiss Cardio Technologies in 2024. The acquisition aims to accelerate commercialization and global expansion of Swiss Cardio's flagship product Cardioplexol. The deal includes worldwide rights to Swiss Cardio's cardioplegia business, enhancing Abacus Medicine's portfolio.
- Medius AGcoreMedius AG handles the marketing and distribution of Cardioplexol in Switzerland. Located at Neue Bahnhofstrasse 160, 4132 Muttenz, Switzerland.
- TAW Pharma (Ireland) LimitedcoreTAW Pharma handles the marketing and distribution of Cardioplexol in Europe. Located at 104 Lower Baggot Street, Dublin 2, D02Y940, Ireland.
Scale indicators2 records
Recent moves7 records
Expansion highlights5 records
Swiss Cardio Technologies competitors and assessment
Company assessmentDirect peers
- Dr. Franz Köhler Chemie: German specialty pharmaceutical company best known as the originator/marketer of Custodiol (histidine-tryptophan-ketoglutarate cardioplegia solution), the established standard in crystalloid cardioplegia. Direct competitor to Cardioplexol in cardiac surgical myocardial protection.
- Essential Pharmaceuticals: US-based specialty pharma focused on Custodiol HTK cardioplegia solution for organ preservation and cardiac surgery. Direct competitor in the same cardioplegia category targeting transplant and cardiac surgery centers.
Broad incumbents
- Terumo Cardiovascular (Terumo Corporation): Cardiac surgery division of Terumo offering perfusion products including cardioplegia delivery systems and solutions. A broader incumbent player with overlapping products in the cardiac surgery supply chain where Cardioplexol competes.
- LivaNova: Global medical device company with a cardiovascular segment serving cardiac surgery centers — overlapping customer base (hospitals and perfusionists) and procedural ecosystem in which cardioplegia is consumed.
- Getinge (formerly Maquet/Getinge): Established manufacturer of cardiac surgery, perfusion, and cardioplegia delivery equipment. A broad incumbent serving the same surgical suites that buy cardioplegic solutions.
- ICU Medical: Specialty medical device and pharmaceuticals company with hospital infusion and critical-care products overlapping with cardioplegia delivery and clinical use.
- B. Braun: Large pharmaceutical and medical device manufacturer offering hospital injectables and infusion solutions — a broad competitor in the cardioplegia-adjacent hospital pharmaceutical supply category.
- Fresenius Kabi: Specialty pharma/infusion company with hospital injectable products and a clinical nutrition portfolio that overlaps with the perioperative pharmaceutical supply where Cardioplexol is positioned.
- Pfizer Hospital Business (Cardiovascular legacy portfolio): Diversified pharma incumbent with historical presence in cardiovascular and surgical pharmaceuticals, including products sold into the same hospital cardiac surgery setting.
Others
- AdvaCare Pharma: Global pharmaceutical manufacturer/distributor of hospital pharmaceuticals including injectable cardiology-related products — an adjacent pharmaceutical manufacturer with limited direct cardioplegia presence but overlapping distribution and customer base.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
Swiss Cardio Technologies social profiles
Digital presenceSwiss Cardio Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
Swiss Cardio Technologies leadership team
Management profileNumber of profiles
Profiles11 records
Swiss Cardio Technologies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Swiss Cardio Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Swiss Cardio Technologies
What does Swiss Cardio Technologies do?
Swiss Cardio Technologies AG develops and commercializes Cardioplexol®, a novel standardized ultra-low-volume cardioplegic solution used in cardiovascular surgery to provide myocardial protection during operative procedures. The company holds exclusive global license rights to Cardioplexol® and has obtained marketing approvals in 10 EU countries and Switzerland, distributing the product through pharmaceutical partners Medius AG (Switzerland) and TAW Pharma (Europe).
Is Swiss Cardio Technologies a public or private company?
Swiss Cardio Technologies is a private company. It is classified as corporate owned and is currently acquired.
When was Swiss Cardio Technologies founded?
Swiss Cardio Technologies was founded in 2008. It employs 1 to 10 people.
Where is Swiss Cardio Technologies based?
Swiss Cardio Technologies is headquartered in Stansstad, Switzerland, in the Europe region.
How does Swiss Cardio Technologies make money?
One revenue line is on record: pharmaceutical product sales.
Who are Swiss Cardio Technologies's main competitors?
Direct peers on record are Dr. Franz Köhler Chemie and Essential Pharmaceuticals. Broad incumbents are Terumo Cardiovascular (Terumo Corporation), LivaNova, Getinge (formerly Maquet/Getinge), ICU Medical, B. Braun, Fresenius Kabi and Pfizer Hospital Business (Cardiovascular legacy portfolio). AdvaCare Pharma is listed as an others.
Does Swiss Cardio Technologies have an API?
No public API is recorded for Swiss Cardio Technologies.
What industry is Swiss Cardio Technologies in?
Swiss Cardio Technologies's product category is Cardiovascular Pharmaceuticals. Its primary akta.pro industry code is HLAIACAG, Cardiology & Vascular Specialty Pharmaceuticals, with a secondary code of HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity). Its NAICS code is 42345 and its SIC code is 2834.